GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Graft Polymer (UK) PLC (LSE:GPL) » Definitions » Inventories, Finished Goods

Graft Polymer (UK) (LSE:GPL) Inventories, Finished Goods : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Graft Polymer (UK) Inventories, Finished Goods?

Graft Polymer (UK)'s quarterly finished goods declined from Dec. 2022 (£0.06 Mil) to Jun. 2023 (£0.00 Mil) but then stayed the same from Jun. 2023 (£0.00 Mil) to Dec. 2023 (£0.00 Mil).

Graft Polymer (UK)'s annual finished goods increased from May. 2021 (£0.00 Mil) to Dec. 2022 (£0.06 Mil) but then declined from Dec. 2022 (£0.06 Mil) to Dec. 2023 (£0.00 Mil).


Graft Polymer (UK) Inventories, Finished Goods Historical Data

The historical data trend for Graft Polymer (UK)'s Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graft Polymer (UK) Inventories, Finished Goods Chart

Graft Polymer (UK) Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - - - 0.06 -

Graft Polymer (UK) Semi-Annual Data
May18 May19 May20 May21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial - - 0.06 - -

Graft Polymer (UK) Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Graft Polymer (UK) (LSE:GPL) Business Description

Traded in Other Exchanges
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment.

Graft Polymer (UK) (LSE:GPL) Headlines

No Headlines